Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume

European Heart Journal

Volumn 29, Issue 19, 2008, Pages 2343-2350

  Adlbrecht, Christopher ^a   Kommata, Spyridoula ^a   Hülsmann, Martin ^a   Szekeres, Thomas ^a   Bieglmayer, Christian ^a   Strunk, Guido ^b   Karanikas, Georgios ^a   Berger, Rudolf ^a   Mörtl, Deddo ^a   Kletter, Kurt ^a   Maurer, Gerald ^a   Lang, Irene M ^a   Pacher, Richard ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b VIENNA UNIVERSITY OF ECONOMICS AND BUSINESS   (Austria)

Author keywords

Anaemia; Erythropoietin; Haemodilution; Heart failure; Hepcidin; Plasma volume

Indexed keywords

CHROMIUM 51; ERYTHROPOIETIN; HEMOGLOBIN; HEPCIDIN; IRON;

ADULT; AGED; ANEMIA; ARTICLE; CELL VOLUME; CONTROLLED STUDY; DISEASE ASSOCIATION; ERYTHROCYTE; ERYTHROPOIESIS; FEMALE; HEART FAILURE; HEMATOLOGICAL PARAMETERS; HEMODILUTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PLASMA VOLUME; PRIORITY JOURNAL; PSEUDOANAEMIA; RETICULOCYTE;

ANEMIA, IRON-DEFICIENCY; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; ERYTHROCYTE VOLUME; ERYTHROPOIETIN; FEMALE; HEART FAILURE; HEMOGLOBINS; HUMANS; IRON; MALE; MIDDLE AGED; PLASMA VOLUME;

EID: 53249107656     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn359     Document Type: Article

References (35)

1. Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, Sarnak MJ. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001;38:955-962.
2. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 2003;107:223- 225.
3. Ezekowitz JA. Anemia in patients with advanced heart failure. J Am Coll Cardiol 2007;49:2301; author reply 2302.
4. Steinborn W, Doehner W, Anker SD. Anemia in chronic heart failure-frequency and prognostic impact. Clin Nephrol 2003;60(Suppl. 1):S103-S107.
5. Tang YD, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 2006;113:2454-2461.
6. Komajda M. Anemia in chronic heart failure: should we treat it and how? J Am Coll Cardiol 2007;49:763-764.
7. van Veldhuisen DJ, McMurray JJ. Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial. Eur J Heart Fail 2007;9:110-112.
8. Beck-da-Silva L, Rohde LE, Pereira-Barretto AC, de Albuquerque D, Bocchi E, Vilas-Boas F, Moura LZ, Montera MW, Rassi S, Clausell N. Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia. J Card Fail 2007;13:14-17.
9. Bolger AP, Bartlett FR, Penston HS, O'Leary J, Pollock N, Kaprielian R, Chapman CM. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006;48:1225-1227.
10. Silverberg DS, Blum M, Peer G, Kaplan E, Iaina A. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 1996;72:413-417.
11. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Loreal O. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001;276:7811-7819.
12. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood 2006;108:3204-3209.
13. Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG, Tsagalou EP, Maroulidis GD, Alexopoulos GP, Kanakakis JE, Anastasiou-Nana MI. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006;48:2485-2489.
14. Androne AS, Katz SD, Lund L, LaManca J, Hudaihed A, Hryniewicz K, Mancini DM. Hemodilution is common in patients with advanced heart failure. Circulation 2003;107:226-229.
15. Westenbrink BD, Visser FW, Voors AA, Smilde TD, Lipsic E, Navis G, Hillege HL, van Gilst WH, van Veldhuisen DJ. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J 2007;28:166-171.
16. Recommended methods for measurement of red-cell and plasma volume: International Committee for Standardization in Haematology. J Nucl Med 1980;21:793-800.
17. Standard techniques for the measurement of red-cell and plasma volume. A report by the International Committee for Standardization in Hematology (ICSH): Panel on Diagnostic Applications of Radioisotopes in Haematology. Br J Haematol 1973;25:801-814.
18. Feldschuh J, Enson Y. Prediction of the normal blood volume. Relation of blood volume to body habitus. Circulation 1977;56:605-612.
19. Handelman GJ, Levin NW. Iron and anemia in human biology: a review of mechanisms. Heart Fail Rev 2008;25:25.
20. Messinezy M, Pearson TC. The classification and diagnostic criteria of the erythrocytoses (polycythaemias). Clin Lab Haematol 1999;21:309-316.
21. Pearson TC, Guthrie DL, Simpson J, Chinn S, Barosi G, Ferrant A, Lewis SM, Najean Y. Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br J Haematol 1995;89:748-756.
22. Stoiser B, Mortl D, Hulsmann M, Berger R, Struck J, Morgenthaler NG, Bergmann A, Pacher R. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 2006;36:771-778.
23. Cazzola M, Beguin Y. New tools for clinical evaluation of erythron function in man. Br J Haematol 1992;80:278-284.
24. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002;162:1401-1408.
25. Swaak A. Anemia of chronic disease in patients with rheumatoid arthritis: aspects of prevalence, outcome, diagnosis, and the effect of treatment on disease activity. J Rheumatol 2006;33:1467-1468.
26. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002;39:1780-1786.
27. Finch CA, Miller LR, Inamdar AR, Person R, Seiler K, Mackler B. Iron deficiency in the rat. Physiological and biochemical studies of muscle dysfunction. J Clin Invest 1976;58:447-453.
28. Brownlie TT, Utermohlen V, Hinton PS, Giordano C, Haas JD. Marginal iron deficiency without anemia impairs aerobic adaptation among previously untrained women. Am J Clin Nutr 2002;75:734-742.
29. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, Brosh D, Laniado S, Schwartz D, Yachnin T, Shapira I, Gavish D, Baruch R, Koifman B, Kaplan C, Steinbruch S, Iaina A. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000;35:1737-1744.
30. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, Schwartz D, Yachnin T, Steinbruch S, Shapira I, Laniado S, Iaina A. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001;37:1775-1780.
31. Silverberg DS, Wexler D, Blum M, Tchebiner JZ, Sheps D, Keren G, Schwartz D, Baruch R, Yachnin T, Shaked M, Schwartz I, Steinbruch S, Iaina A. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003;18:141-146.
32. Roe MA, Spinks C, Heath AL, Harvey LJ, Foxall R, Wimperis J, Wolf C, Fairweather-Tait SJ. Serum prohepcidin concentration: no association with iron absorption in healthy men; and no relationship with iron status in men carrying HFE mutations, hereditary haemochromatosis patients undergoing phlebotomy treatment, or pregnant women. Br J Nutr 2007;97:544-549.
33. Merle U, Fein E, Gehrke SG, Stremmel W, Kulaksiz H. The iron regulatory peptide hepcidin is expressed in the heart and regulated by hypoxia and inflammation. Endocrinology 2007;148:2663-2668.
34. Kemna EH, Tjalsma H, Podust VN, Swinkels DW. Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. Clin Chem 2007;53:620-628.
35. Graziadei I, Weiss G, Bohm A, Werner-Felmayer G, Vogel W. Unidirectional upregulation of the synthesis of the major iron proteins, transferrin-receptor and ferritin, in HepG2 cells by the acute-phase protein alpha1-antitrypsin. J Hepatol 1997;27:716-725.